Pharma and rare disease advocates press FDA at public hearing on Makary's National Priority Voucher pilot, urging formal rulemaking; 21 vouchers awarded so far.
The pharma industry and rare disease advocates voiced concerns about the transparency and fairness of the Commissioner’s National Priority Voucher pilot program.
The program faces …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts
Drug companies, patient groups urge FDA to pause commissioner’s voucher program
Will Makary's FDA voucher program survive?
Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more
FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails
Radiopharmaceutical shows promise in post-Pluvicto setting
Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US
Accelerating Targeted Gene Expression Analysis in Drug Development
On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National…
The White House has used the program to reward companies that help its political goals.
Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas. In the meeting,…
RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across…
Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review…
